| Literature DB >> 11877469 |
Loren D Erickson1, Brigit G Durell, Laura A Vogel, Brian P O'Connor, Marilia Cascalho, Teruhito Yasui, Hitoshi Kikutani, Randolph J Noelle.
Abstract
Agonistic alpha CD40 Ab's have been shown to be potent immune adjuvants for both cell- and humoral-mediated immunity. While enhancing short-lived humoral immunity, the administration of a CD40 agonist during thymus-dependent immune responses ablates germinal center formation, prematurely terminates the humoral immune response, blocks the generation of B cell memory, and prevents the generation of long-lived bone marrow plasma cells. Interestingly, some of these effects of heightened CD40 engagement could be mimicked by enhancing the magnitude of antigen-specific T cell help. Taken together, these studies demonstrate that as the magnitude of CD40 signaling intensifies, the fate of antigen-reactive B cells can be dramatically altered. These are the first studies to describe the multifaceted function of CD40 in determining the fate of antigen-reactive B cells and provide novel insights into how CD40 agonists can short-circuit humoral immunity.Entities:
Mesh:
Substances:
Year: 2002 PMID: 11877469 PMCID: PMC150892 DOI: 10.1172/JCI14110
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808